Secondary Outcome
Over the follow-up period there were a total of 57 722 MACEs: 988 (34%) and 56 734 (38%) among statin initiator vs noninitiator person-trials. After propensity score overlap weighting, statin initiation had 4% lower risk of MACE (hazard ratio, 0.96; 95% CI, 0.91-1.02), but the results were not statistically significant (